AstraZeneca’s CAMBRIA-1 trial of experimental breast cancer therapy camizestrant has emerged as a focal near-term driver for the drugmaker, according to analysis from BofA Securities. The firm left its recommendation unchanged at "buy" and held a price objective of 16,500 pence, compared with a current share price of 13,796 pence.
Why CAMBRIA-1 stands out
BofA analysts identify two structural reasons to view CAMBRIA-1 more optimistically than AstraZeneca’s other late-stage camizestrant study, SERENA-4.
First, the analysts say the patient population enrolled in CAMBRIA-1 likely occupies an intermediate position in endocrine sensitivity - not as responsive as a typical adjuvant cohort, but more endocrine sensitive than patients in first-line metastatic settings. In the report, BofA pointed to Roche’s lidERA trial, which read out positively in the adjuvant setting, and to Roche’s persevERA study, which did not succeed in first-line metastatic patients, as evidence that endocrine sensitivity can materially influence trial outcomes.
Key opinion leaders quoted in the analysis suggested CAMBRIA-1 patients might be more likely to respond to endocrine-directed therapy than a standard adjuvant population. The rationale offered is that patients with truly endocrine-resistant disease have a higher likelihood of having already progressed to the metastatic setting, reducing their representation in CAMBRIA-1.
Second, CAMBRIA-1 assesses camizestrant as a monotherapy - a trial design that mirrors Roche’s lidERA study. BofA notes that SERENA-4, by contrast, tests camizestrant in combination with a CDK4/6 inhibitor. The bank cautioned that combining a selective estrogen receptor degrader - or SERD - with a CDK4/6 inhibitor could obscure the measurable benefit attributable to the SERD itself, citing debates around prior studies such as PARSIFAL.
Timing and data considerations
CAMBRIA-1’s primary completion date is listed as April 2027. Following the earlier-than-expected lidERA readout from Roche, some market participants have speculated that CAMBRIA-1 could produce interim results sooner than planned. BofA highlighted that those expectations should be tempered because the trial’s statistical powering assumptions have not been disclosed.
The bank remains more cautious on SERENA-4, which is expected to report results in the second half of 2026. BofA’s analysts said they do not see meaningful molecular differences between camizestrant and the Roche compound that failed in persevERA, nor do they observe material distinctions in available Phase 2 efficacy data. While AstraZeneca’s larger SERENA-4 study could improve the chance of reaching statistical significance, BofA warned that any measured benefit might still fall short of being clinically meaningful.
Patient selection challenges highlighted
Patient mix has the potential to affect outcomes, the report noted. As an example, de novo patients made up only 19% of the persevERA population, versus 34% in Novartis’ MONALEESA-2 study. In persevERA, 60% of participants had visceral disease - a subgroup that performed worse in the trial, with a hazard ratio of 0.94 compared with 0.80 among patients without visceral involvement.
Commercial outlook and program timeline
BofA said that even if SERENA-4 underdelivers, consensus risk-adjusted peak sales estimates for camizestrant of roughly $3.5 billion across indications remain supported by the adjuvant opportunity alone. The bank notes pivotal Phase 3 adjuvant data are expected in 2027.
A second adjuvant study, CAMBRIA-2, is not expected to report until 2030 and is described as being more closely aligned in design with Roche’s lidERA trial.
Valuation context
BofA’s 16,500 pence price objective is based on roughly 18 times its 2027 earnings estimate, representing a premium to the sector average of about 15 times. The analysts said the valuation reflects AstraZeneca’s comparatively stronger projected growth profile: earnings per share are expected to rise about 12% annually between 2027 and 2030, versus roughly 8% for the sector, while revenue is forecast to grow around 7% between 2027 and 2032 compared with approximately 3% for peers.
What to watch next
Key near-term items for investors include the timing and content of any interim CAMBRIA-1 updates, the full data from SERENA-4 expected in the second half of 2026, and the pivotal Phase 3 adjuvant readout anticipated in 2027. Patient selection characteristics and subgroup performance - particularly visceral disease and de novo status - are additional variables that could influence both trial outcomes and commercial expectations.